Open AccessDPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis
Author(s) -
Yan Yang,
Zhongxiang Cai,
Jingjing Zhang
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0251916
Subject(s) - meta analysis , odds ratio , publication bias , medicine , cochrane library , confidence interval , covid-19 , funnel plot , diabetes mellitus , coronavirus , medline , disease , bioinformatics , biology , endocrinology , infectious disease (medical specialty) , biochemistry
Aims DPP-4 inhibitors are predicted to exert a protective effect on the progression of coronavirus disease 2019 (COVID-19). We conducted this meta-analysis to investigate this hypothesis. Methods Four databases, namely, PubMed, Web of Science, EMBASE and the Cochrane Library, were used to identify studies on DPP-4 and COVID-19. The outcome indicators were the mortality of COVID-19. Funnel plots, Begg’s tests and Egger’s tests were used to assess publication bias. Results Four articles were included with a total of 1933 patients with COVID-19 and type 2 diabetes. The use of DPP-4 inhibitors was negatively associated with the risk of mortality (odds ratio (OR) = 0.58 95% confidence interval (CI), 0.34–0.99). Conclusions DPP-4 inhibitors may improve the mortality of patients with COVID-19 and type 2 diabetes. As few relevant studies are available, more large-scale studies need to be performed.